The correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer

Basit Öğe Kaydı
dc.authoridYORUK, YENER/0000-0001-6309-3054
dc.authorwosidKocak, Zafer/AEG-7828-2022
dc.authorwosidYoruk, Yener/W-4285-2017
dc.contributor.authorAltaner, Semsi
dc.contributor.authorYoruk, Yener
dc.contributor.authorTokatli, Fusun
dc.contributor.authorKocak, Zafer
dc.contributor.authorTosun, Birsen
dc.contributor.authorGuresci, Servet
dc.contributor.authorKutlu, Kemal
dc.date.accessioned2024-06-12T10:50:45Z
dc.date.available2024-06-12T10:50:45Z
dc.date.issued2006
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAims and background: Thyroid transcription factor (TTF-1) is a tissue-specific transcription factor expressed in the epithelial cells of thyroid and lung. The aim of this study was to evaluate the relationship between the expression of TTF-1 and clinicopathological parameters in pulmonary adenocarcinoma and adenosquamous carcinoma. Methods: Resection material of pneumonectomies and lobectomles of 39 patients was retrospectively examined. Twenty-eight patients were diagnosed with adenocarcinoma and 11 with adenosquamous carcinoma. Tumors were classified into 3 groups: a strongly positive group (++) with double dagger 50% tumor cells positive for TTF-1; a weakly positive group (+) with 1-49% positive tumor cells; and a negative group (-) with less than 1% or no positive tumor cells. Analysis was performed with Kaplan-Meier estimates and log-rank tests. Results: Staining for TTF-1 was negative in 10 cases. There was focal staining in 9 cases, while there was diffuse staining in 20 (51%) cases out of 39, and 15 (75%) of these were adenocarcinomas. There was a statistically significant association between TTF-1 and lymph node metastases (P = 0.029). No relationship was found between TTF-1 positivity and disease-free and overall survival. Conclusions: TTF-1 expression may be a predictor of lymph node metastases. Additional work in a larger group of patients is needed to better assess the utility of this marker.en_US
dc.identifier.doi10.1177/030089160609200411
dc.identifier.endpage326en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue4en_US
dc.identifier.pmid17036524en_US
dc.identifier.scopus2-s2.0-33749566321en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage323en_US
dc.identifier.urihttps://doi.org/10.1177/030089160609200411
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18089
dc.identifier.volume92en_US
dc.identifier.wosWOS:000240920300011en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdenocarcinomaen_US
dc.subjectAdenosquamous Carcinomaen_US
dc.subjectLungen_US
dc.subjectPrognosisen_US
dc.subjectTTF-1en_US
dc.subjectTranscription Factor-Ien_US
dc.subjectEnhancer-Binding Proteinen_US
dc.subjectCell Carcinomasen_US
dc.subjectGeneen_US
dc.subjectExpressionen_US
dc.titleThe correlation between TTF-1 immunoreactivity and the occurrence of lymph node metastases in patients with lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu